Evidence map›Paper›PMID 34362159›Full record

ArticleJournal of clinical medicine2021

Can VA-ECMO Be Used as an Adequate Treatment in Massive Pulmonary Embolism?

Raphaël Giraud, Matthieu Laurencet, Benjamin Assouline, Amandine De Charrière, Carlo Banfi, Karim Bendjelid

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
6.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Observational
  11. Article
  12. Article
  13. Role of Extracorporeal Membrane Oxygenation in the Treatment of Massive Pulmonary Embolism.The International journal of angiology : official publication of the International College of Angiology, Inc · 2024
    Review
  14. Development and assessment of novel assist device for cardiac cannulation.International journal of computer assisted radiology and surgery · 2024
    Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Raphaël GiraudIntensive Care Unit, Geneva University Hospitals, 1205 Geneva, Switzerland.ORCID 0000-0001-5956-8643
Matthieu LaurencetIntensive Care Unit, Geneva University Hospitals, 1205 Geneva, Switzerland.
Benjamin AssoulineIntensive Care Unit, Geneva University Hospitals, 1205 Geneva, Switzerland.
Amandine De CharrièreIntensive Care Unit, Geneva University Hospitals, 1205 Geneva, Switzerland.
Carlo BanfiGeneva Hemodynamic Research Group, Faculty of Medicine, University of Geneva, 1205 Geneva, Switzerland.
Karim BendjelidIntensive Care Unit, Geneva University Hospitals, 1205 Geneva, Switzerland.ORCID 0000-0002-7921-7207
University of Geneva · CHUniversity Hospital of Geneva · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMassive acute pulmonary embolism (MAPE) with obstructive cardiogenic shock is associated with a mortality rate of more than 50%. Venoarterial extracorporeal membrane oxygenation (VA-ECMO) has been increasingly used in refractory cardiogenic shock with very good results. In MAPE, although it is currently recommended as part of initial resuscitation, it is not yet considered a stand-alone therapy. MATERIAL AND

methodsAll patients with MAPE requiring the establishment of VA-ECMO and admitted to our tertiary intensive care unit were analysed over a period of 10 years. The characteristics of these patients, before, during and after ECMO were extracted and analysed.

resultsA total of 36 patients were included in the present retrospective study. Overall survival was 64%. In the majority of cases, the haemodynamic and respiratory status of the patient improved significantly within the first 24 h on ECMO. The 30-day survival significantly increased when ECMO was used as stand-alone therapy (odds ratio (OR) 15.58, 95% confidence interval (CI) 2.65-91.57,

conclusionsThe present retrospective study is certainly one of the most important in terms of the number of patients with MAPE and shock treated with VA-ECMO. This short-term mechanical circulatory support, used as a stand-alone therapy in MAPE, allows for the optimal stabilisation of patients.

Indexed as

cardiogenic shockmassive acute pulmonary embolismthrombolysisVA-ECMO

Identifiers

PMID34362159
PMCPMC8348430
OpenAlexW3189087922

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.